Biologics drugs are derived from a wide variety of natural sources such as human, animal, or microorganisms by using biotechnology. Moreover, Biologics include a wide variety of products such as blood and blood components, vaccines, tissues, allergenic, gene therapy, somatic cells, and recombinant therapeutic proteins. Novel therapies and new technologies are emerging to create new biologics, which holds a prominent future for the biologics market.
Increasing robust pipeline of biologics is expected to drive growth of the global biologics market.
Key players in the market have number of biopharmaceuticals products, which are in clinical trials and are expected to receive approval in the near future. Thus, robust pipeline of biopharmaceutical products is expected to significantly drive growth of global biologics market over the forecast period. For instance, Amgen Inc. has monoclonal antibody AMG 820 and AMG 966 in phase I clinical trials, monoclonal antibody AMG 301, AMG 557, AMG 714, and Tezepelumab, in phase II clinical trials; and monoclonal antibody Aimovig (erenumab), EVENTIYTM (romosozumab), Tezepelumab, and Prolia (denosumab) in phase III clinical trials.
0
